Robin John is co-founder and Chief Executive Officer of Eventide. He is responsible for the overall leadership of the organization, and under his leadership, the firm has grown into a leader within values based investing.
Prior to Eventide, Mr. John held leadership roles for Bank of New York Mellon. He has also served as a business consultant for Grant Thornton. He has a degree in Economics from Tufts University.
Finny Kuruvilla, MD, PhD serves as CIO for Eventide Funds and Portfolio Manager for the Eventide Gilead Fund and the Eventide Healthcare & Life Sciences Fund.
Dr. Kuruvilla has a unique background in healthcare, statistics, and investing. Concurrent with Eventide, from 2008 through 2016, he was a Principal at Clarus Ventures, a leading healthcare and life sciences venture capital firm. Prior to joining Eventide, from 2005-2008, he was a postdoctoral research scientist in medical genetics at the Broad Institute of Harvard and MIT. From 2003-2007, he was resident, chief resident, and clinical fellow at the Brigham and Women’s Hospital and Children’s Hospital Boston.
Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree in Chemistry from Caltech.
Harry Nelson serves as Director of Distribution for Eventide. He is responsible for leading several business development initiatives including managing Key Account relationships and leading Product Development. He also leads Eventide’s Investment Consulting Group.
Prior to joining Eventide in 2017, Mr. Nelson was President of GuideStone Capital Management, LLC. Before that, he served in business development roles at GuideStone and Golden Capital Management. He holds the Certified Investment Management Analyst certification, administered by Investment Management Consultants Association and taught in conjunction with the Wharton School of Business at the University of Pennsylvania.
Mr. Nelson earned a B.A. in Political Science from The Citadel and a M.A. in Leadership from Dallas Baptist University.
Jason Myhre serves as Director of Advocacy at Eventide. In this capacity, he serves as an advocate for “investing that makes the world rejoice”® and the Business 360 investing philosophy to investor, business, and popular audiences.
In prior roles at Eventide, Mr. Myhre led Marketing and Sales. Before joining Eventide, he worked in internal sales and managed key customer relationships for Altec.
Mr. Myhre holds a M.S. and a B.S. in Biological Engineering from the University of Florida.
Peter Luiso serves Eventide as CCO, managing Eventide’s compliance program.
Prior to joining Eventide in June 2016, Mr. Luiso held several roles at Fidelity Investments, most recently Deputy CCO of Fidelity’s Strategic Advisers Funds, where he provided regulatory guidance to many of Fidelity’s investment advisers, broker-dealers, and retirement businesses. Before that, he served as a Senior Enforcement Attorney for the U.S. Securities and Exchange Commission and as Trial Counsel for the New York Stock Exchange.
Mr. Luiso holds a bachelor’s degree in Criminal Justice from Northeastern University in Boston and a J.D. from Georgia State University College of Law in Atlanta.
Dolores Bamford, CFA, serves as Director of Investment Research and Portfolio Manager for the Eventide Multi-Asset Income Fund, the Eventide Dividend Opportunities Fund, the Eventide Limited-Term Bond Fund, and the Eventide Core Bond Fund.
Ms. Bamford has over 25 years of investment experience. Prior to joining Eventide in 2019, she was with Goldman Sachs Asset Management for 13 years (2002-2015), most recently as Managing Director and Portfolio Manager on U.S. Value Equity. She also led Goldman Sachs’s U.S. Responsible Equity investments and co-led the Global Sustain Equity investments. Previously, she was with Putnam Investments for 10 years (1992-2002), where she served as Senior Vice President and Portfolio Manager and Analyst on multiple value investments. Before that, she was with Fidelity Investments (1988-1990), where she served in investment research.
Ms. Bamford holds an S.M. in Management from the MIT Sloan School of Management, a dual-M.A. in Theology and Church History from Gordon-Conwell Theological Seminary, and a B.A. in Economics from Wellesley College. She is a CFA Charterholder and member of the Boston Society of Security Analysts.
Andrew Singer, CFA, serves as an Associate Portfolio Manager on the Eventide Dividend Opportunities Fund and Senior Research Analyst for other Eventide funds. He is primarily responsible for making investment recommendations and monitoring existing portfolio investments by conducting fundamental, financial, and valuation analyses.
Prior to joining Eventide, Mr. Singer held investment analyst positions at Credit Suisse, BlackRock, and John Hancock, where he focused on small- and mid-cap equities across a variety of sectors. He has a bachelor’s degree in Quantitative Economics from Tufts University and an MBA from Babson College. He holds the Chartered Financial Analyst designation and is a member of the CFA Society Boston and CFA Institute.
Anant Goel serves as Portfolio Manager for the Eventide Exponential Technologies Fund and Senior Research Analyst on other Eventide funds.
Mr. Goel has a diverse background having grown up and lived in India, Hong Kong, UK, USA and China, which combined with his academic and professional interests, allow him to incorporate a diverse set of perspectives in his investment decision process. He has been passionate about responsible investing from early in his career. He has served as a Research Analyst at Eventide since 2016, leading its technology focused research. In 2015, during his M.B.A. program, he worked at Adage Capital Management, a long/short hedge fund. From 2011-2014, he served as an Analyst for NewQuest Capital Partners, a Private Equity firm in Hong Kong, where he was responsible for evaluating new investment opportunities for funds across Asia. From 2008-2011, he lived and worked in Beijing, China where he studied Mandarin and worked on start-up companies and other investment projects.
Mr. Goel holds an M.B.A. from the MIT Sloan School of Management where he was selected as a Teaching Assistant (TA) for finance courses for both Executive M.B.A. and M.B.A. students. He also holds a Bachelors of Science (HONS) from the University of Warwick, UK in Economics.
Joy Ghosh, PhD, serves as a Senior Research Analyst at Eventide, with a primary focus on healthcare and life sciences.
Dr. Ghosh has a cross-disciplinary background in biopharma/biotech R&D, business development/M&A, and healthcare investing. Prior to joining Eventide, from 2017-2020, he was an Associate/Vice President at Bain Capital for their Life Sciences Fund. From 2016-2017, he was a Senior Manager at Biogen. From 2009-2016, he was an Investigator at the Novartis Institutes of Biomedical Research. Prior to Novartis, he was a postdoctoral scientist at Brigham and Women’s Hospital/Harvard Medical School and Boston University School of Medicine.
Dr. Ghosh holds a PhD from the University of Washington, Seattle in Biomolecular Structure and Design and a bachelor’s degree in Biochemistry from the University of Texas at Austin.
Faina Rozental serves as a Research Analyst for Eventide. She is primarily responsible for evaluating and monitoring new and existing investment opportunities in the portfolios.
Ms. Rozental has an MBA with certificates in finance and sustainability from the MIT Sloan School of Management. During her time at MIT, she worked at Goldman Sachs and the MIT Office of Sustainability. Prior to MIT, she managed social due diligence at Root Capital, an agricultural impact investor, and earlier was responsible for OECD research sales in North America.
Ms. Rozental holds a B.A./M.A. in Economics from Boston University.
Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Funds’ ethical values screening criteria could cause them to under-perform similar funds that do not have such screening criteria.
Investors should consider a fund’s investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at https://www.eventidefunds.com/prospectus or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.